Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice

被引:9
作者
Millar, JL [1 ]
Millar, BC
Powles, RL
Steele, JPC
Clutterduck, RD
Mitchell, PLR
Cox, G
Forssen, E
Catovsky, D
机构
[1] Inst Canc Res, McElwain Labs, Acad Dept Haematol & Cytogenet, Sutton SM2 5NG, Surrey, England
[2] Royal Marsden NHS Trust, Leukaemia Unit, Sutton, Surrey, England
[3] NeXstar Pharmaceut Inc, San Dimas, CA USA
关键词
liposomal vincristine; NOD/SCID mouse; human leukemia;
D O I
10.1046/j.1365-2141.1998.00831.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-obese diabetic NOD/SCID mice have been used to grow human leukaemia as a systemic disease. The animals were inoculated with leukaemic cells obtained from a 36-year-old male with early B-cell precursor acute lymphoblastic leukaemia and on day 15 were given the first of three weekly injections of 1 mg/kg vincristine or equimolar liposomal vincristine. The development of leukaemia in the mice was monitored by taking weekly blood samples and measuring the cell content by flow cytometry. The median time to 50% human cells in the peripheral blood of mice treated with free vincristine was 41 d from the start of treatment compared with 49 d for mice treated with liposomal vincristine (P < 0.01). The median day of death for mice treated with free vincristine was 47 d from the start of treatment and 57 d for mice receiving liposomal vincristine (P < 0.01), thus providing a 21% increase in lifespan for animals treated with the liposomal preparation. There was slightly greater weight loss in mice treated with free vincristine than those given liposomal vincristine. Measurement of in vitro colony forming bone marrow progenitor cells in similarly treated, tumour-free mice, showed no difference in progenitor cell survival between mice that received either type of vincristine. We conclude that encapsulating vincristine in liposomes improves the therapeutic index of this drug measured in mice bearing human leukaemia. This may lead to use of the drug in conventional combination chemotherapy with greater safety or, in this setting, at higher dosage.
引用
收藏
页码:718 / 721
页数:4
相关论文
共 15 条
[1]   PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF VINCRISTINE ENCAPSULATED IN STERICALLY STABILIZED LIPOSOMES [J].
ALLEN, TM ;
NEWMAN, MS ;
WOODLE, MC ;
MAYHEW, E ;
USTER, PS .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (02) :199-204
[2]  
BOWMAN NL, 1994, CANCER RES, V54, P2830
[3]   EFFECT OF OXYGEN-TENSION ON HEMATOPOIETIC AND FIBROBLAST CELL-PROLIFERATION INVITRO [J].
BRADLEY, TR ;
HODGSON, GS ;
ROSENDAAL, M .
JOURNAL OF CELLULAR PHYSIOLOGY, 1978, 97 (03) :517-522
[4]   RECENT ADVANCES IN LIPOSOMAL DRUG-DELIVERY SYSTEMS [J].
CHONN, A ;
CULLIS, PR .
CURRENT OPINION IN BIOTECHNOLOGY, 1995, 6 (06) :698-708
[5]  
HAIM N, 1994, CANCER, V73, P2515, DOI 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO
[6]  
2-G
[7]  
HOELZER D, 1994, SEMIN HEMATOL, V31, P1
[8]   LIPOSOME-ENCAPSULATED VINCRISTINE - PRECLINICAL TOXICOLOGIC AND PHARMACOLOGICAL COMPARISON WITH FREE VINCRISTINE AND EMPTY LIPOSOMES IN MICE, RATS AND DOGS [J].
KANTER, PM ;
KLAICH, GM ;
BULLARD, GA ;
KING, JM ;
BALLY, MB ;
MAYER, LD .
ANTI-CANCER DRUGS, 1994, 5 (05) :579-590
[9]  
MAYER LD, 1990, CANCER RES, V50, P575
[10]  
ROTHENBERG M, 1991, COMPLICATIONS CANC M, P3